Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (31)

2022

  1. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

  2. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

    Liver International, Vol. 42, Núm. 8, pp. 1891-1901

  3. The complex management of hepatocellular carcinoma: a major need for expertise

    Revista Espanola de Enfermedades Digestivas

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  3. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  4. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

  5. Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study

    Liver Transplantation, Vol. 27, Núm. 12, pp. 1767-1778

2019

  1. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

    Journal of Hepatology, Vol. 70, Núm. 5, pp. 874-884

2018

  1. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR

    Oncotarget, Vol. 9, Núm. 56, pp. 30869-30882

  2. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events

    Hepatology, Vol. 67, Núm. 2, pp. 612-622

2017

  1. Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers

    Medicina Clinica, Vol. 149, Núm. 2, pp. 61-71

2016

  1. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH

    Medicina Clinica, Vol. 146, Núm. 11, pp. 511.e1-511.e22

  2. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 719-726

2010

  1. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma

    European Journal of Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 1239-1244

  2. Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma

    Gastroenterologia y Hepatologia, Vol. 33, Núm. 10, pp. 741-752

2009

  1. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?

    Cancer, Vol. 115, Núm. 3, pp. 616-623

2008

  1. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma

    Hepatology, Vol. 47, Núm. 1, pp. 97-104

  2. Malignant Tumours

    Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition (Blackwell Publishing Ltd), pp. 1437-1463

2007

  1. Hepatoma

    Medical Care of the Liver Transplant Patient: Third Edition (Blackwell Publishing Ltd), pp. 119-138